Domestic in Medical Technology

Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study

... our products; changes in general industry and market conditions, including domestic and international growth rates and general domestic and international economic conditions, including interest rate and ...

China Animal Welfare Law Under Review While 36,000 Dogs Culled

... States and focuses its campaigns on improving the welfare of wild and domestic animals by reducing the commercial exploitation of animals, protecting ... both on the ground and in the halls of government to safeguard wild and domestic animals and seeks to motivate the public to prevent cruelty to animals and ...

R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges

... Analysis at the National, State, and Local Levels , the study found that domestic R&D spending by biopharmaceutical companies equaled roughly $65,000 ... for future growth - and recovery - is a sector's contribution to gross domestic product. According to the study, the sector's direct contribution to the ....

Comparative Study Shows Significant Bone In-growth and Advanced Clinical Outcomes Using Zimmer's Trabecular Metal(TM) Technology

... our products; changes in general industry and market conditions, including domestic and international growth rates and general domestic and international economic conditions, including interest rate and ...

VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease

... To participate in the conference call, please dial 888-684-1280 for domestic callers and 913-312-0952 for international callers. A telephone replay of ... November 14, 2008. To access the replay, please dial 888-203-1112 for domestic callers and 719-457-0820 for international callers and reference ...

Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation

... call, replay and webcast are open to all interested parties. domestic callers: 1-800-299-0148 International callers: 1-617-801-9711 ... Internet, at http://www.alexza.com, or via phone at 1-888-286-8010 for domestic callers or 1-617- 801-6888 for international callers. The reference number ...

AHF Seeks White House Clarification After Press Room Flap Over CDC's HIV Numbers

... questions from this White House Press Room exchange on a crucial domestic AIDS issue for us not to ask the White House and Ms. Perino for ... the White House response to this pending CDC announcement of a much higher domestic HIV rate? And does the White House support the fact that the CDC seems to ...

AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic

... in the U.S., underscores the degree to which HIV/AIDS is still a critical domestic issue. The U.S. message for World AIDS Day 2007 is clear: leadership is ... of the reality of HIV/AIDS in America. The devastating impact of the domestic HIV/AIDS epidemic deserves public attention and increased government ...

Leading AIDS Groups Turn Up The Heat on '08 Presidential Candidates

... the U.S. has yet to develop its own national strategy to combat the domestic HIV/AIDS crisis. AIDSVote.org is a nonpartisan voter and candidate ... progress against HIV/AIDS in the U.S. and abroad. The website includes domestic and global AIDS platforms, which detail how the next president of the U.S. ...

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

... including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and ...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

... including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and ...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

... technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description ...

Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences

... technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and ...

Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases

... including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and ...

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and ...

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

... technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description ...

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

... technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description ...

Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting

... adverse governmental rulings or regulations, including any FDA regulations or rulings; the company's ability to comply with international and domestic regulatory requirements; possible adverse Medicare or other third-party reimbursement policies or adverse changes in those policies; any inability by ...

Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status

... call is 78345594. The replay of the conference call may be accessed via the Internet, at www.alexza.com , or via phone at 888-286-8010 for domestic callers or 617-801-6888 for international callers. The reference number for the replay of the call is 16474219. About Alexza ...

Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting

... technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and ...

FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia

... May 7, 2009, at 1:30 PM ET and will be accessible until Thursday, May 14, 2009, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 55054292. The conference call will be broadcast simultaneously on ...

Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier

... The call is scheduled for April 23, 2009, at 11:00 a.m. EDT (8:00 a.m. PDT). To participate in the conference call, please dial 866-727-3220 for domestic callers and 706-643-1591 for international callers. The conference ID is 95994112. To access the audio broadcast or the subsequent archived ...

Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results

... Ph.D., Vice President, Clinical Development, will host the conference call. The conference call may be accessed by dialing 877.874.1565 for domestic callers and 719.325.4758 for international callers. Please specify to the operator that you would like to join the "Lorcaserin BLOOM Trial Results" ...

Worldwide Cost Estimate for Alzheimer's and Dementia Is US$315.4 Billion

... Direct costs as well as costs of informal care were estimated by combining prevalence estimates, country and region specific data on Gross domestic Product per person, and average wage with results from previously published cost-of-illness studies in different countries. The Global Impact ...

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

... technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment; and other risks and ...

TissueGene Announces Regulatory Allowance to Initiate Phase IIa Study of TG-C in South Korea for Osteoarthritis of the Knee

... "And I believe our success thus far can be attributed primarily to the strategic alliance between TissueGene, Kolon and KLS. By bridging our domestic and international resources, this business model has not only enabled for rapid preclinical and clinical development, but has allowed for innovative ...

Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial

... including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and ...

Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments

... technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment; and other risks and ...

Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

... including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and ...

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)

... technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and ...

Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration

... technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment; and other risks and ...

American Dairy Provides Business Update

... to quality, the Company has also added additional testing equipment to its already extensive testing and quality control procedures. domestic and International Recognition American Dairy's Feihe brand was named one of China's 500 most influential brands at The World Brand Summit jointly ...

Kyowa Hakko Kirin Announces Development Policy for Anti-Parkinson's Disease Drug KW-6002 (Istradefylline)

... Kirin Co., Ltd. (Chiyoda-ku, Tokyo Japan; President, Dr. Yuzuru Matsuda) announced on January 15 (Tokyo Time) that it has decided to continue the domestic development of its proprietary anti-Parkinson's disease drug KW-6002 (generic name: Istradefylline) and move it forward with a Phase 3 clinical trial ...

Delcath Adds Dr. Pamela R. Contag to Its Board of Directors

... Contag, Ph.D., to Delcath's Board of Directors. Dr. Contag is a proven corporate executive with extensive experience working with international and domestic investors. (LOGO: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ) Dr. Contag founded Cobalt Technologies, Inc. in ...

Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial

... is 61907318. The replay of the conference call may be accessed via the Internet, at http://www.alexza.com , or via phone at 888-286-8010 for domestic callers or 617-801-6888 for international callers. The reference number for the replay of the call is 85181265. About Acute Agitation ...

Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients

... including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and ...

Positive Phase 1 Clinical Trial Results for Transdermal Lidocaine

... technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations. ...

FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain

... technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description ...

Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union

... including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and ...

Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer

... including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and ...